Valuation: SENN AB

Market Cap 17Cr 0 1.77Cr 1.52Cr 1.42Cr 1.3Cr 2.44Cr 169.49Cr 2.47Cr 6.54Cr 85Cr 6.65Cr 6.51Cr 281.61Cr P/E 2024
-10.5x
P/E 2025 -15.5x
Enterprise Value 16Cr 0 1.69Cr 1.45Cr 1.35Cr 1.24Cr 2.32Cr 161.49Cr 2.35Cr 6.23Cr 81Cr 6.34Cr 6.2Cr 268.33Cr EV / Sales 2024
2.87x
EV / Sales 2025 2.96x
Free-Float
75.1%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 52 19/08/2021
Director of Finance/CFO 65 01/11/2016
Chief Operating Officer 44 01/01/2014
Director TitleAgeSince
Chairman 78 01/01/2015
Director/Board Member 61 17/06/2019
Director/Board Member 76 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
+8.24%+10.75% - - 1.77Cr
+2.16%+5.05%+99.92%+299.85% 414.79Cr
-7.79%+18.77%+208.18%+31.38% 375.51Cr
+1.24%+2.57%+36.48%+61.24% 340.13Cr
+3.45%+7.26%+274.79%+454.28% 251.48Cr
-3.61%+3.84%-21.05%-19.77% 240.96Cr
-0.88%+16.87%+27.81% - 148.38Cr
+4.22%+51.58%+252.65%-18.26% 128.73Cr
-2.40%-5.13%+16.63%+41.86% 100.26Cr
-2.72%-2.82%-36.30%+1.72% 55Cr
Average +0.19%+11.21%+95.46%+106.54% 228.38Cr
Weighted average by Cap. -0.76%+10.61%+113.05%+140.74%

Financials

2024 2025
Net sales 5.77Cr 0 60.93L 52.19L 48.83L 44.7L 83.89L 58Cr 85L 2.25Cr 29Cr 2.29Cr 2.24Cr 97Cr 5.8Cr 0 61.22L 52.44L 49.07L 44.92L 84.3L 59Cr 85.41L 2.26Cr 29Cr 2.3Cr 2.25Cr 97Cr
Net income -1.78Cr -0 -18.85L -16.15L -15.11L -13.83L -25.95L -18Cr -26.3L -69.61L -9.06Cr -70.78L -69.24L -30Cr -1.16Cr -0 -12.24L -10.48L -10L -9L -16.85L -12Cr -17.07L -45.19L -5.88Cr -45.95L -44.95L -19Cr
Net Debt -3.78Cr -0 -39.95L -34.22L -32.02L -29.31L -55L -38Cr -55.73L -1.48Cr -19Cr -1.5Cr -1.47Cr -64Cr -79.12L -0 -8L -7L -7L -6L -11.5L -7.99Cr -11.66L -30.85L -4.02Cr -31.37L -30.69L -13Cr
Logo SENN AB
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Employees
-